Introduction {#s1}
============

Improved diagnostic testing represents a key component of tuberculosis (TB) control [@pmed.1001074-Small1]--[@pmed.1001074-Keeler1], and inadequate case detection is a major hurdle for effective control of the TB epidemic. Sputum smear microscopy, the current backbone of TB diagnosis worldwide, misses 50% of all cases and is often performed under suboptimal laboratory conditions [@pmed.1001074-Corbett1]--[@pmed.1001074-Steingart1]. Thus, if targets for TB control are to be achieved, newer diagnostic tools for active TB must be used. On the basis of available evidence [@pmed.1001074-Pai1],[@pmed.1001074-Pai2], the World Health Organization (WHO) currently recommends several technologies for TB diagnosis [@pmed.1001074-World1], including culture of *Mycobacterium tuberculosis* using commercial liquid media (e.g., mycobacteria growth indicator tube \[MGIT\], BD Diagnostics) or noncommercial methods (e.g., microscopic observation drug susceptibility \[MODS\]), and more recently, rapid molecular testing with the Xpert MTB/RIF system (Cepheid, Inc.) [@pmed.1001074-Boehme1],[@pmed.1001074-World2]. However, TB culture often takes weeks to obtain results, and all currently recommended diagnostic tests (other than microscopy) require infrastructure currently unavailable in many settings [@pmed.1001074-Pai1],[@pmed.1001074-Pai2],[@pmed.1001074-Getahun1]. Although promising, technologies such as MODS and Xpert MTB/RIF are yet to be scaled up in India. Before investing in additional infrastructure, it is important to assess whether other, more immediately accessible, TB diagnostic tests might be cost-effective.

Serological tests for active TB are based on detection of antibodies elicited by antigens of *Mycobacterium tuberculosis* that are recognized by the humoral immune system. Many serological tests utilize an ELISA format, while several others are available as rapid point-of-care tests (e.g. immunochromatographic, lateral flow assays). Thus, serological tests are attractive because they are faster and simpler to perform than most sputum-based methods [@pmed.1001074-Perkins2]. However, as demonstrated in a recent updated systematic review [@pmed.1001074-Steingart2], existing evidence supporting commercial serological tests is inconsistent and of low quality. Although no international guideline recommends their use, serological tests for active TB are readily available and widely used in parts of the developing world, including India and at least 16 of 21 other high-burden countries [@pmed.1001074-Grenier1]. Thus, while unlikely to be as accurate as TB culture, serological tests might still be preferred over sputum smear microscopy, and serology might also be economically attractive relative to culture and molecular tests given fewer infrastructure requirements, faster turnaround time, and higher volume of usage.

The economic implications of serological testing for TB are substantial. In India, at least 13 different TB serological kits are on the market ([Table 1](#pmed-1001074-t001){ref-type="table"}), and an estimated 1.5 million serological tests for active TB are performed every year (primarily in the private medical sector), at a cost of over US\$15 million for testing alone [@pmed.1001074-Grenier1],[@pmed.1001074-World3]. To better understand the economic and epidemiological consequences of serological testing for active TB in India, we analyzed costs and effectiveness from the perspective of the combined public and private TB control sector of the health care system.
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###### Serological assays for tuberculosis on the Indian market.

![](pmed.1001074.t001){#pmed-1001074-t001-1}

  Company                                              Kit                           Assay Technique              Sensitivity and Specificity from Package Insert                            URL
  --------------------------------------- ------------------------------ --------------------------------------- ------------------------------------------------- --------------------------------------------------------
  Anda Biologicals, Strasbourg, France            anda TB-ELISA                           ELISA                         Not listed, refers to publications                     <http://www.andabiologicals.com>
  Omega Diagnostics, Alva, Scotland         Pathozyme TB Complex Plus                     ELISA                                    37% and 100%                               <http://www.omegadiagnostics.com>
  Tulip Group, Goa                                  Qualisa TB                            ELISA                                    100% and 99%                                  <http://www.tulipgroup.com>
  Tulip Group, Goa                                Serocheck-MTB           Rapid[a](#nt101){ref-type="table-fn"}                    100% and 100%                                 <http://www.tulipgroup.com>
  Span Diagnostics, Surat                        TB Spot Ver 2.0          Rapid[a](#nt101){ref-type="table-fn"}                     80% and 99%                                    <http://www.span.co.in>
  Bhat Biotech, Bangalore                      Bhat Bioscan TB card       Rapid[a](#nt101){ref-type="table-fn"}                     83% and 99%                                 <http://www.bhatbiotech.com/>
  Span Diagnostics, Surat                            Mycowell                             ELISA                       "Superior sensitivity and specificity"                       <http://www.span.co.in>
  J Mitra, New Delhi                          TB IgG, IgM, IgA Elisa                      ELISA                                     80% and 97%                                   <http://www.jmitra.co.in>
  JB Trop Dis Res Centre, Sevagram               SEVA *TB ELISA*                          ELISA                                     97% and 99%                              <http://www.jbtdrc.org/SEVA_TB.pdf>
  S.D. Bio Standard Diagnostic India           SD BIOLINE Rapid TB        Rapid[a](#nt101){ref-type="table-fn"}                     98% and 99%                             <http://sdbiostandard.tradeindia.com/>
  Bisen Biotech, Gwalior                          TB SCREEN TEST          Rapid[a](#nt101){ref-type="table-fn"}                     94% and 98%                               <http://www.bisenbiotechindia.com>
  Lab-care Diagnostics Pvt Ltd, Sarigam       Accucare Rapid TB test      Rapid[a](#nt101){ref-type="table-fn"}          \>80% sensitivity and specificity          <http://www.labcarediagnostics.com/RapidTest_sub.html>
  Tashima Inc, Bangalore                   TB IgG/IgM 3 Line Rapid test   Rapid[a](#nt101){ref-type="table-fn"}                    93% and 100%                                    <http://www.tashima.net>

Rapid chromatographic immunoassay.

Methods {#s2}
=======

We constructed a decision-analytic model to estimate the costs and effectiveness of serological testing for active TB. The basic model structure ([Figure 1](#pmed-1001074-g001){ref-type="fig"}) was adapted from a previously described cost-effectiveness analysis of novel TB diagnostics [@pmed.1001074-Dowdy1]. This static model evaluates outcomes (including secondary TB transmission) in a cohort of TB suspects. We took as our study population a hypothetical cohort of 1.5 million adult TB suspects in India, presenting for diagnosis in settings with access to serological testing. Thus, this cohort provides a conservative estimate of costs and outcomes among all Indian patients receiving serological testing for active TB in a given year. These patients were assumed to have TB prevalence, HIV prevalence, and access to antiretroviral therapy representative of adults with suspected TB in India as a whole [@pmed.1001074-Joint1],[@pmed.1001074-Special1].

![Study decision tree.\
Depicted is a simplified version of the analytic framework for this decision analysis. The square represents a decision node, circles chance nodes, and triangles terminal nodes. The branch of the decision node (sputum smear + serology) is compared to similar branches corresponding to scenarios of no TB-specific diagnosis, sputum smear only, and sputum smear plus TB culture (commercial liquid media), as described in the text. Probabilities, costs, and DALYs are calculated at each terminal node according to the parameters described in [Table 2](#pmed-1001074-t002){ref-type="table"}. ARV, antiretroviral therapy; +, positive; −, negative.](pmed.1001074.g001){#pmed-1001074-g001}
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###### Parameter estimates used in the model.

![](pmed.1001074.t002){#pmed-1001074-t002-2}

  Parameter                                                             Base Value   Range for Sensitivity Analysis                            Reference
  -------------------------------------------------------------------- ------------ -------------------------------- -------------------------------------------------------------
  TB dynamics^a^                                                                                                     
  Probability of death, untreated smear-positive TB                        0.70                0.5--0.95                               [@pmed.1001074-Corbett1]
  Probability of death, untreated smear-negative TB                        0.20                0.15--0.25                              [@pmed.1001074-Corbett1]
  Secondary TB infections per year, smear-positive TB                       10                   8--12                                  [@pmed.1001074-Styblo1]
  Relative infectiousness of smear-negative TB                             0.22                0.16--0.28                                [@pmed.1001074-Behr1]
  Fraction of new TB cases that are smear-positive                         0.53                0.4--0.66                               [@pmed.1001074-Corbett1]
  **Characteristics of TB diagnosis**                                                                                
  Prevalence of active TB among persons with suspected active TB           0.14                0.11--0.18                              [@pmed.1001074-Special1]
  Sensitivity of clinician diagnosis[b](#nt103){ref-type="table-fn"}       0.53                0.40--0.67                               [@pmed.1001074-World4]
  Sensitivity for smear-positive TB, serology (anda-TB)                    0.76                0.63--0.87                             [@pmed.1001074-Steingart2]
  Sensitivity for smear-negative TB                                                                                  
  MGIT TB culture (single specimen)                                        0.73                0.55--0.91                              [@pmed.1001074-Cruciani1]
  Serology                                                                 0.59                0.40--0.85                             [@pmed.1001074-Steingart2]
  Specificity for active TB                                                                                          
  Clinician diagnosis^b^                                                   0.94                0.75--1.0                                [@pmed.1001074-Keeler1]
  Sputum smear microscopy (two smears)                                     0.97                 0.9--1.0                              [@pmed.1001074-Steingart1]
  MGIT TB culture                                                          0.99                0.95--1.0                               [@pmed.1001074-Cruciani1]
  Serology                                                                 0.87                0.74--0.98             [@pmed.1001074-Steingart2] [c](#nt104){ref-type="table-fn"}
  Time to TB diagnosis                                                                                               
  MGIT TB culture                                                          8 wk                 1--4 mo                                 [@pmed.1001074-Dowdy2]
  Sputum smear, serology                                                   1 wk                 3--14 d                   [@pmed.1001074-Pronyk1],[@pmed.1001074-Salaniponi1]
  Loss to follow-up                                                                                                  
  MGIT TB culture                                                          0.25                0.19--0.31                                      Estimated
  Sputum smear, serology                                                   0.15                0.11--0.19                   [@pmed.1001074-Squire1],[@pmed.1001074-Creek1]
  **Characteristics of TB treatment**                                                                                
  Proportion of treated TB patients who die                               0.045               0.033--0.056                              [@pmed.1001074-World4]
  Proportion of treated HIV/TB patients who die                           0.090               0.068--0.114                              [@pmed.1001074-World4]
  Proportion of treated TB patients infectious at 1 y                     0.045               0.033--0.056                              [@pmed.1001074-World4]
  **HIV/TB**                                                                                                         
  HIV prevalence, general population                                       0.3%               0.225%--0.4%                              [@pmed.1001074-Joint1]
  HIV prevalence, patients with TB                                         5.3%                4.0%--6.6%                               [@pmed.1001074-World4]
  Proportion of HIV-infected patients with ART access                      0.10               0.075--0.125                              [@pmed.1001074-Joint1]
  **Costs and effectiveness, US\$**                                                                                  
  Unit cost, independent laboratory                                                                                  
  Sputum smear microscopy (two smears)                                   US\$3.62             US\$1--US\$5                             [@pmed.1001074-Special1]
  TB culture (MGIT)                                                       US\$20             US\$10--US\$30                            [@pmed.1001074-Mueller1]
  Serology                                                                US\$20             US\$10--US\$30                            [@pmed.1001074-Special1]
  Mean cost of treating one case of TB                                  US\$82.40           US\$60--US\$100                             [@pmed.1001074-World4]
  DALY weights[a](#nt102){ref-type="table-fn"}                                                                       
  Active TB                                                               0.264               0.198--0.330                              [@pmed.1001074-Murray1]
  TB treatment                                                            0.132               0.099--0.165                                     Estimated
  Life expectancy after TB cure (y)                                         40                   30--50                  [@pmed.1001074-Ministry1],[@pmed.1001074-Institute1]

Parameter values for HIV-positive patients are excluded from this table owing to low HIV prevalence but were incorporated into the model and can be found in reference [@pmed.1001074-Dowdy1].

In the absence of any TB-specific microbiological test.

Excludes studies not performed in developing countries.

ART, antiretroviral therapy.

To evaluate various diagnostic strategies, we conducted a two-stage analysis. In the first stage, we sought to identify the best initial test for TB. In the second stage, we sought to evaluate the optimal diagnostic strategy for improved TB diagnosis in settings where sputum smear microscopy is routinely performed. The baseline scenario for the first analysis assumed that the study population receives the combination of tests (e.g., chest X-ray \[CXR\]) and clinical strategies (e.g., antibiotic trials) that is typical in India, with the exception of using no TB-specific microbiological test (including sputum smear microscopy, culture, or serology). We assumed that the country-wide smear-negative TB case detection rate in India approximates the ability of clinicians to successfully diagnose TB in this situation. To evaluate the most appropriate initial test for TB in this situation, we modeled the addition to the baseline scenario of sputum smear microscopy versus serological testing using anda-tb ELISA (Anda Biologicals; the most widely studied and used serological test in India) [@pmed.1001074-Steingart2]. In the second analytic stage, we assumed that sputum smear microscopy was performed as an initial test, followed by either anda-tb ELISA or automated liquid culture on smear-negative specimens. Our primary outcome for all analyses was the incremental cost-effectiveness ratio (ICER) relative to the reference scenario for each analytic stage.

Serology is primarily available in India through stand-alone and large network (chain) private laboratories which also offer TB cultures. Thus, we assumed that the population had existing access to serology (at market prices), and that similar access to TB culture could be established by constructing an appropriate laboratory facility; there are currently 27 reference laboratories capable of culture and drug-susceptibility testing, accredited by the Indian Revised National TB Control Programme (RNTCP). We assumed that sputum smear and serology could be performed by send-out testing to a public or private laboratory with a 1-wk turnaround time, and that TB culture would incur additional delays of 8 wk for specimen incubation, reporting of results, and initiation of treatment [@pmed.1001074-Dowdy2]. These assumptions were tested in sensitivity analyses.

Regarding costs, we conservatively estimated that anda-TB would cost US\$20 per person with suspected active TB on the basis of data from private labs in India [@pmed.1001074-Grenier1],[@pmed.1001074-World3], although the total cost per patient often exceeds US\$40 (because three antibodies---IgA, IgG, and IgM---are often requested). We assumed that the cost per TB culture was US\$20, approximately equal to the cost of automated MGIT culture, including the costs of laboratory construction and overheads, when run at half-maximum throughput in Zambia [@pmed.1001074-Mueller1]. Patients diagnosed with TB were assumed to be treated according to RNTCP national standards.

Accuracy for each test was estimated from published literature, including meta-analyses where available [@pmed.1001074-Steingart2],[@pmed.1001074-Steingart3],[@pmed.1001074-Cruciani1]. For TB serology, we used the sensitivity and specificity of anda-TB, the most widely studied test according to a recently updated meta-analysis [@pmed.1001074-Steingart2]. Since anda-TB is likely to outperform more poorly studied in-house serological tests and less accurate rapid test formats [@pmed.1001074-Steingart2], and laboratory accuracy is likely to exceed that in the field, our analysis likely overestimates the accuracy of serology as actually performed in practice. A full listing of estimated parameter values is given in [Table 2](#pmed-1001074-t002){ref-type="table"}.

We assumed that all incremental costs and effects of TB treatment occur during the first year after presentation with symptoms of active TB (i.e., that any patient who would be successfully diagnosed with TB would be diagnosed within 1 y of presentation). Patients with active TB at the end of this year are assumed to remain infectious for an additional year [@pmed.1001074-Styblo1], acknowledging that the period of infectivity depends on numerous variables including HIV status, age, gender, and type (e.g., cavitary nature) of disease. Outcomes (e.g., death) occurring within that year are discounted over the cohort\'s lifetime, which was the analytic time horizon. We lack reliable data on the costs of hospitalization for TB, lost wages due to TB, or treatment for other related conditions (e.g., bacterial pneumonia). Thus, we adopted the perspective of the Indian TB control sector, including both the public RNTCP and those elements of the private health care sector devoted to diagnosis and treatment of TB. Our primary outcome was the incremental cost per disability-adjusted life year (DALY) averted. All costs were converted to US dollars using historical exchange rates and inflated to the year 2010 using the medical care component of the US Consumer Price Index [@pmed.1001074-United1]. We discounted all future costs and effects (DALYs and secondary TB transmissions) by 3% per year, with sensitivity analysis for 0% and 7%.

One-way sensitivity analysis was performed on all parameters across ranges shown in [Table 2](#pmed-1001074-t002){ref-type="table"}, with further two-way sensitivity analysis on those variables to which the model was most sensitive. In the absence of data to suggest a reasonable parameter range, we varied each parameter over +/−25% of its baseline value. Since published estimates of serological test accuracy likely overestimate their actual accuracy in the field, we also evaluated an alternative scenario using the lower bounds of sensitivity and specificity for serological testing from a recent meta-analysis [@pmed.1001074-Steingart2]. Analyses were performed using TreeAge Pro 2009 (TreeAge Software, Inc.).

Results {#s3}
=======

The hypothetical study population of 1.5 million adults with suspected active TB included an estimated 214,000 cases of active TB, or 16% of India\'s annual burden of incident TB [@pmed.1001074-World4]. We estimated that, in the absence of TB-specific microbiological testing (i.e., in the baseline scenario), clinicians would diagnose 114,000 (53%) of these patients with TB on the basis of clinical judgment and nonmicrobiological tests (e.g., chest X-ray \[CXR\], antibiotic therapeutic trials) alone. Addition of sputum smear microscopy to this scenario of no TB-specific testing resulted in diagnosis of an estimated 44,000 more cases of TB, or 44% of remaining undiagnosed cases ([Table 3](#pmed-1001074-t003){ref-type="table"}). Replacing sputum smear with serological testing resulted in an estimated 14,000 more diagnosed cases of TB than did sputum smear, but also resulted in 121,000 additional false-positive diagnoses relative to microscopy. Because the cases detected by sputum smear are assumed to be more infectious than those detected by serology, smear was estimated to avert 102,000 more DALYs and 32,000 more secondary cases than did serology, at approximately one-fourth the incremental cost. If performed only on smear-negative specimens, TB culture was both cheaper and more effective (i.e., dominant) compared with serological testing ([Table 3](#pmed-1001074-t003){ref-type="table"}). For each additional smear-negative TB case diagnosed by serology, more than six additional false positives were inappropriately diagnosed.

10.1371/journal.pmed.1001074.t003

###### Cost-effectiveness of diagnostic strategies for 1.5 million persons with suspected active TB in India.

![](pmed.1001074.t003){#pmed-1001074-t003-3}

  Diagnostic Test                                                                   Cost (US\$)    Additional TB Cases Treated   Additional False-Positive Cases Treated   Secondary Cases Averted   DALYs Averted   Incremental DALYs Averted   Incremental Cost per DALY Averted (US\$)
  -------------------------------------------------------------------------------- -------------- ----------------------------- ----------------------------------------- ------------------------- --------------- --------------------------- ------------------------------------------
  **Performed alone, relative to no microbiological testing**                                                                                                                                                                                   
  Sputum smear microscopy                                                           11.9 million             44,000                              36,000                            443,000              623,000               623,000                               19
  anda-TB serology                                                                  47.5 million             58,000                              157,000                           411,000              520,000             (Dominated)                        (Dominated)
  **Performed on smear-negative specimens only, relative to sputum smear alone**                                                                                                                                                                
  MGIT culture                                                                      27.6 million             26,000                              12,000                            112,000              130,000               130,000                              213
  anda-TB serology                                                                  39.0 million             24,000                              152,000                           112,000              110,000             (Dominated)                        (Dominated)

When we conducted one-way sensitivity analysis of all variables across the ranges specified in [Table 2](#pmed-1001074-t002){ref-type="table"}, no scenario was identified in which serology was either less costly or more effective than sputum smear microscopy alone, nor serology plus sputum smear more cost-effective than MGIT culture plus sputum smear. Reducing the time to culture-based diagnosis from 8 wk (with 25% loss to follow-up) to 2 wk (with 15% loss to follow-up, similar to serology) reduced the incremental cost-effectiveness of culture plus smear, relative to smear alone, from US\$213 to US\$188.

The incremental cost-effectiveness of serology was most sensitive to the sensitivity and specificity of the serological test. By contrast, the influence of specificity on the cost-effectiveness of sputum smear was small (incremental cost per DALY averted of US\$19 versus US\$14 for sputum smear specificity of 97% versus 100%). Thus, comparing serology alone to sputum smear, we performed two-way sensitivity analysis around sensitivity and specificity of serology, plus three-way sensitivity analysis sequentially incorporating the price of serology and proportion of TB cases presenting with smear-positive TB. For serological testing to achieve equivalent effectiveness (in terms of DALYs averted) to sputum smear microscopy, sensitivity for both smear-positive and smear-negative TB would be required to exceed 81%--86%, depending on specificity ([Figure 2A](#pmed-1001074-g002){ref-type="fig"}). These thresholds are less stringent in settings where a lower proportion of TB patients present with smear-positive disease ([Figure 2B](#pmed-1001074-g002){ref-type="fig"}). Because of the excess cost of treating false positives, serology (with any sensitivity) would need to achieve a specificity of \>0.92 before a test, even with a price of US\$0.01, could be less costly to the TB control sector than sputum smear. When we evaluated the lower bounds of published values for the specificity (0.74) and smear-positive sensitivity (0.63) of serological testing to compensate for possible publication bias, serology was estimated to avert 171,000 fewer DALYs and cost US\$48.1 million more than sputum smear microscopy alone. When added to sputum smear microscopy, serology would need to achieve exceptional sensitivity and specificity (e.g., 70% sensitivity and 97% specificity for smear-negative TB) to achieve more favorable cost-effectiveness ratios than TB culture ([Figure 3](#pmed-1001074-g003){ref-type="fig"}).

![Three-way sensitivity analysis: sensitivity and specificity of serology for active TB.\
Specificity and sensitivity (for smear-positive and smear-negative TB) would be required to achieve values above the primary line for serology to be more effective than sputum smear microscopy alone. The vertical and horizontal lines denote the 95% credible intervals of estimated accuracy from published studies of anda-TB [@pmed.1001074-Steingart2], the most widely used serological test in India. (A) compares serology alone against sputum smear microscopy alone in a setting where 53% of TB patients are smear-positive (base case scenario), while (B) considers a scenario in which only 40% of TB patients are smear-positive.](pmed.1001074.g002){#pmed-1001074-g002}

![Two-way sensitivity analysis: serology versus culture for diagnosis of drug-sensitive TB.\
For the incremental cost-effectiveness ratio (ICER) to be more favorable for serology than for TB culture using commercial liquid media (MGIT) in the base-case scenario (73% sensitivity and 99% specificity), the sensitivity and specificity of serology for smear-negative TB must achieve values above the primary line. The estimated sensitivity and specificity of serology in the base case are 59% and 87%, respectively [@pmed.1001074-Steingart2].](pmed.1001074.g003){#pmed-1001074-g003}

Discussion {#s4}
==========

This study, in a hypothetical cohort of 1.5 million adult Indian persons with suspected active TB, suggests that sputum smear microscopy remains the most cost-effective initial diagnostic test for active TB, across a wide range of plausible parameter estimates. In areas where quality-assured microscopy is already available and resources are sufficient, liquid TB culture is a more cost-effective addition than serology. As an addition to sputum smear plus clinical judgment, serology detects more than six false positives for every new smear-negative TB case appropriately diagnosed, and from the economic perspective of the Indian TB control sector, is less favorable than (i.e., dominated by) other diagnostic options.

This study highlights the substantial adverse economic consequences of serological TB testing in India. Although most serological testing in India is performed in the private sector, patients diagnosed with TB (including false positives) are often sent for treatment in public facilities [@pmed.1001074-Pantoja1]. The scale-up of the RNTCP is estimated to have added over US\$88 billion in economic benefit to India over the last 10 y through country-wide implementation of directly observed therapy, short-course (DOTS) services, including sputum smear microscopy [@pmed.1001074-Goodchild1]. Given the scale of the RNTCP\'s activities and its limited budget, any diagnostic strategy demanding additional resources may divert those resources from further improvement of sputum smear microscopy or engagement of the private sector to provide broader access to microscopy or other new WHO-endorsed diagnostics. If serology is used as a replacement for sputum smear microscopy in one-third of the estimated 1.5 million patients receiving serologic TB diagnosis annually in India [@pmed.1001074-World3], we estimate that the Indian TB control sector would lose an estimated US\$11.9 million (approximately one-sixth the annual budget of the RNTCP) [@pmed.1001074-World3], generate 11,000 additional secondary cases of TB (nearly 1% of all incident TB cases in India) [@pmed.1001074-World4], treat 40,000 false-positive patients unnecessarily, and cause 34,000 DALYs.

Although we designed this analysis primarily as an evaluation of serological testing, our secondary results regarding TB culture suggest that, from the perspective of the Indian TB control sector, MGIT would be cost-effective, assuming that systems could be put in place to translate culture results consistently into treatment decisions [@pmed.1001074-Dowdy2]. While there is no universal standard for cost-effectiveness of interventions, those whose cost per DALY averted is less than a country\'s per-capita gross domestic product (GDP, US\$3,100 in India [@pmed.1001074-Central1]) are considered by the Commission for Macroeconomics and Health and WHO to be "very cost-effective" [@pmed.1001074-Commission1]. Sputum smear microscopy is estimated to cost US\$19 per DALY averted, and addition of TB culture to sputum smear US\$213 per DALY averted, speaking to the importance of efforts to increase India\'s TB control budget and to deploy TB diagnostics in settings where current diagnostic standards are poor [@pmed.1001074-Dowdy1]. Indeed, the RNTCP will require substantially higher resources to scale-up improved and new TB diagnostics in India, as it begins a new phase (2012--2017).

One important, and often overlooked, consideration in cost-effectiveness analyses of TB diagnostics is the role of false-positive results [@pmed.1001074-Dowdy3]. Most prior cost-effectiveness analyses of TB diagnostics (e.g., [@pmed.1001074-Keeler1],[@pmed.1001074-Dowdy1]) have focused on the importance of high sensitivity in controlling the TB epidemic, assessing small costs (e.g., the cost of first-line TB drugs) to patients incorrectly diagnosed with TB. However, in a setting where a diagnostic test could result in over six times as many incremental false-positive as true-positive diagnoses ([Table 3](#pmed-1001074-t003){ref-type="table"}), other considerations including loss of faith in the health care system, ethical concerns of physicians, and adverse effects of TB therapy may be increasingly relevant. Furthermore, we assumed a setting where one in seven persons with suspected TB has active disease; where this ratio is lower, low-specificity diagnostics will perform even more poorly. Thus, our analysis may be biased against those diagnostics (i.e., smear and TB culture) with highest specificity.

A key limitation to this study is its reliance on published data for parameter estimates, many of which are subject to substantial variability, as well as the lack of direct data on the full costs (including purchase of equipment, laboratory scale-up, and training of staff) of culture. Nevertheless, we were unable to generate a model in which serology was more effective than sputum smear or more cost-effective than TB culture despite variation of each individual parameter by at least 25% of its baseline value. More importantly, published data on the sensitivity and specificity of serological testing are limited. For example, a total of 686 patients (105 from developing countries) have been reported in the published literature for anda-TB: the most widely studied serological test, available since 1990 [@pmed.1001074-Steingart2]. This number compares with 1,730 patients reported in the first publication of Xpert MTB/RIF, a novel molecular test for TB [@pmed.1001074-Boehme1], and over 14,000 specimens evaluated by MGIT [@pmed.1001074-Cruciani1]. Since published estimates likely overestimate the true performance of novel diagnostic tests, and in-house ELISA and rapid tests perform worse than commercial ELISA-based assays [@pmed.1001074-Steingart2],[@pmed.1001074-World5], our analysis based on published estimates of a commercial ELISA may overestimate the effectiveness and cost-effectiveness of serology as implemented in actual practice.

We also acknowledge other limitations to our approach. First, we were unable to adopt a societal perspective, owing to the lack of reliable data on the societal costs of TB diagnosis and treatment in India. Thus, while internally consistent, our analysis should not be used to compare the cost-effectiveness of improved TB diagnostics to interventions in other areas of the health care sector. Our estimate of the cost-effectiveness of sputum smear microscopy plus TB treatment (US\$19 per DALY averted) is nonetheless similar to that of the World Bank (US\$7--US\$11 in 2010 dollars for a low-income country) [@pmed.1001074-World6]. Second, since our primary focus was on serology, we limited our analysis to drug-sensitive TB and did not conduct a full costing study for culture. Third, we assume a population (urban and peri-urban) with access to a laboratory capable of performing serology. This population is not representative of the entire Indian population, and results from our model thus should not be generalized to all Indian persons with suspected active TB. Furthermore, the cost of establishing such laboratory services may not be entirely reflected in the market prices for these tests; thus, our model may underestimate the cost of diagnostic testing in areas where laboratory infrastructure is not preexisting. Finally, although we estimated secondary transmissions from our primary cohort, our model has a static 1-y analysis frame and does not account for changes over time including repeated rounds of TB transmission. We may therefore underestimate the long-term cost-effectiveness of improved TB diagnosis [@pmed.1001074-Dowdy4].

These data were presented to a WHO Expert Group that met in July 2010 to review the evidence on TB serological assays. This Expert Group considered the updated meta-analysis on commercial serological tests [@pmed.1001074-Steingart2], as well as data from the present analysis demonstrating that serology is not cost-effective. Based on the Expert Group\'s recommendation, in July 2011, the WHO published a policy statement on commercial serodiagnostic tests for diagnosis of TB. The policy states that Commercial serological tests provide inconsistent and imprecise estimates of sensitivity and specificity. There is no evidence that existing commercial serological assays improve patient-important outcomes, and high proportions of false-positive and false-negative results adversely impact patient safety. Overall data quality was graded as very low, with harms/risks far outweighing any potential benefits (strong recommendation). It is therefore recommended that these tests should not be used in individuals suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status. The WHO policy strongly encourages targeted further research to identify new/alternative point-ofcare tests for TB diagnosis and/or serological tests with improved accuracy [@pmed.1001074-Morris1],[@pmed.1001074-Strategic1].

In conclusion, this cost-effectiveness analysis suggests that, as an initial test for active TB among adults in India, serology results in more DALYs, secondary infections, and false-positive diagnoses than sputum smear microscopy, while increasing per-patient costs to the Indian TB control sector. In areas where high-quality sputum microscopy is available, adding automated liquid culture is more effective and less costly than adding serology. These data have been considered by the WHO in recommending against serological testing for active TB, and will need to be considered by Indian regulatory and governmental agencies that need to implement the WHO recommendations.
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